The use of materials such as organofunctionalized silica for application in solid phase extraction (SPE) allows the preconcentration of several ions, including Pt, and subsequent detection. This work aims to synthesize and characterize an organofunctionalized silica (Sil-TMSDT) with the silylant N’(trimethoxysilyl)propylethylenetriamine and its application as a solid phase in the preconcentration Pt4+ ions in aqueous media, using detection by flame atomization atomic absorption spectroscopy (FAAS). The Fourier-transform infrared spectroscopy (FTIR) spectra and scanning electron microscopy (SEM) coupled with energy-dispersive spectroscopy (EDS) confirmed the aminofunctionalization of the silica. For the adsorption process, a preconcentration mini-column with 200 mg of Sil-TMSDT, a solution of 0.485 mg L−1 of K2[PtCl6] at pH 10 and HNO3 0.5 mol L−1 as eluent were used, obtaining an enrichment factor of 15-fold with retention efficiency higher than 99%. The Pt4+ ion determined by FAAS showed a linear response between 0.02 and 0.40 mg L−1; a linear coefficient where R = 0.9981; a 16-fold preconcentration factor; a limit of quantification (LOQ) and limit of detection (LOD) of 0.045 and 0.014 mg L−1, respectively. The proposal system showed analytical applicability to determining Pt4+ ion in an aqueous medium and could be used to detect traces of this potentially toxic metal in biological fluids such as urine and blood. SPE (SPE Pt SilTMSDT Sil TMSDT (Sil-TMSDT Ntrimethoxysilylpropylethylenetriamine N trimethoxysilyl propylethylenetriamine Pt4 media FAAS. . (FAAS) Fouriertransform Fourier transform FTIR (FTIR SEM (SEM energydispersive energy dispersive EDS (EDS process minicolumn mini column 20 SilTMSDT, TMSDT, Sil-TMSDT 0485 0 485 0.48 L1 L 1 L− K2PtCl6 KPtCl K2 PtCl6 K PtCl K2[PtCl6 HNO 05 5 0. 15fold fold 15 99 99% 002 02 0.0 040 40 0.4 0.9981 09981 9981 16fold 16 LOQ (LOQ LOD (LOD 0045 045 0.04 0014 014 0.01 respectively blood (FAAS 2 048 48 K2PtCl K2[PtCl 9 00 04 4 0.998 0998 998 004 001 01 0.99 099 0.9 09

The synthesis, characterization, cytotoxicity and antitumor activity of platinum(II) complexes coordinated to O-glycoside and analogous is reported. Through the acute toxicity tests, it was possible to fit the complexes into categories according to the OECD protocol. The cis-[PtCl2(C6H14S2O2)-κ2S] complex was classified in category 3 and the cis-[PtCl2(C26H38O12S2)-κ2S] complex was classified in category 4. This result demonstrates the lower toxicity achieved by the glycoside in comparison with its analogous system. Evaluations of tumor masses extracted from mice inoculated with Ehrlich carcinoma demonstrated percent inhibition similar to cisplatin and synthesized platinum complexes. Cisplatin showed 59% inhibition, while cis-[PtCl2(C6H14S2O2)-κ2S] and cis-[PtCl2(C26H38O12S2)-κ2S] complexes presented 57% and 59%, respectively. Although the glycosidic compounds exhibit tumor activity, reported in the literature, the presence of platinum ion was shown to be determinant for antitumor action according with the compounds tested, since the glycosidic ligand presented tumor inhibition of only 38%, with a similar antitumor activity in relation to cisplatin.